Evidence map›Paper›PMID 21767389›Full record

ArticleBreast cancer research : BCR2011

Allele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10.

Petra E A Huijts, Minka van Dongen, Moniek C M de Goeij, Adrian J van Moolenbroek, Freek Blanken, Maaike P G Vreeswijk, Esther M de Kruijf, Wilma E Mesker, Erik W van Zwet, Rob A E M Tollenaar and 3 more

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. LowerBiology · 2024
    Article
  3. Article
  4. Review
  5. Review
  6. Fibroblast growth factor receptor 2 gene (Saudi journal of biological sciences · 2021
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. The FGF/FGFR axis as a therapeutic target in breast cancer.Expert review of endocrinology & metabolism · 2013
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Petra E A HuijtsDepartment of Clinical Genetics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. p.e.a.huijts@lumc.nl
Minka van Dongen
Moniek C M de Goeij
Adrian J van Moolenbroek
Freek Blanken
Maaike P G Vreeswijk
Esther M de Kruijf
Wilma E Mesker
Erik W van Zwet
Rob A E M Tollenaar
Vincent T H B M Smit
Christi J van Asperen
Peter Devilee
Leiden University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSNPs rs2981582 and rs2981578, located in a linkage disequilibrium block (LD block) within intron 2 of the fibroblast growth factor receptor 2 gene (FGFR2), are associated with a mildly increased breast cancer risk. Allele-specific regulation of FGFR2 mRNA expression has been reported previously, but the molecular basis for the association of these variants with breast cancer has remained elusive to date.

methodsmRNA levels of FGFR2 and three fibroblast growth factor genes (FGFs) were measured in primary fibroblast and epithelial cell cultures from 98 breast cancer patients and correlated to their rs2981578 genotype. The phosphorylation levels of downstream FGFR2 targets, FGF receptor substrate 2α (FRS2α) and extracellular signal-regulated kinases 1 and 2 (ERK1/2), were quantified in skin fibroblasts exposed to FGF2. Immunohistochemical markers for angiogenesis and lymphocytic infiltrate were semiquantitatively assessed in 25 breast tumors.

resultsThe risk allele of rs2981578 was associated with increased FGFR2 mRNA levels in skin fibroblasts, but not in skin epithelial cell cultures. FGFR2 mRNA levels in skin fibroblasts and breast fibroblasts correlated strongly in the patients from whom both cultures were available. Tumor-derived fibroblasts expressed, on average, eight times more FGFR2 mRNA than the corresponding fibroblasts from normal breast tissue. Fibroblasts with higher FGFR2 mRNA expression showed more FRS2α and ERK1/2 phosphorylation after exposure to FGF2. In fibroblasts, higher FGFR2 expression correlated with higher FGF10 expression. In 25 breast tumors, no associations between breast tumor characteristics and fibroblast FGFR2 mRNA levels were found.

conclusionsThe influence of rs2981578 genotypes on FGFR2 mRNA expression levels is cell type-dependent. Expression differences correlated well with signaling levels of the FGFR2 pathway. Our results suggest that the increased breast cancer risk associated with SNP rs2981578 is due to increased FGFR2 signaling activity in stromal fibroblasts, possibly also involving paracrine FGF10 signaling.

Indexed as

Gene Expression Regulation, NeoplasticPolymorphism, Single NucleotideAdaptor Proteins, Signal TransducingAgedAllelesBreast NeoplasmsEpithelial CellsFemaleFibroblast Growth Factor 10FibroblastsGenetic Predisposition to DiseaseHumansMembrane ProteinsMiddle AgedMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Adaptor Proteins, Signal TransducingFGF10 protein, humanFGFR2 protein, humanFibroblast Growth Factor 10FRS2 protein, humanMAPK1 protein, humanMembrane ProteinsMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Receptor, Fibroblast Growth Factor, Type 2

Identifiers

PMID21767389
PMCPMC3236336
OpenAlexW2149889705

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.